IL227924B - Preparations and methods of use for determining a4he - Google Patents

Preparations and methods of use for determining a4he

Info

Publication number
IL227924B
IL227924B IL227924A IL22792413A IL227924B IL 227924 B IL227924 B IL 227924B IL 227924 A IL227924 A IL 227924A IL 22792413 A IL22792413 A IL 22792413A IL 227924 B IL227924 B IL 227924B
Authority
IL
Israel
Prior art keywords
he4a
compositions
determination
methods
Prior art date
Application number
IL227924A
Other languages
English (en)
Hebrew (he)
Other versions
IL227924A0 (en
Original Assignee
Fujirebio Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujirebio Diagnostics Inc filed Critical Fujirebio Diagnostics Inc
Publication of IL227924A0 publication Critical patent/IL227924A0/en
Publication of IL227924B publication Critical patent/IL227924B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL227924A 2011-02-17 2013-08-12 Preparations and methods of use for determining a4he IL227924B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/025321 WO2012112160A1 (en) 2011-02-17 2011-02-17 Compositions and methods of use for determination of he4a

Publications (2)

Publication Number Publication Date
IL227924A0 IL227924A0 (en) 2013-09-30
IL227924B true IL227924B (en) 2019-01-31

Family

ID=46672864

Family Applications (1)

Application Number Title Priority Date Filing Date
IL227924A IL227924B (en) 2011-02-17 2013-08-12 Preparations and methods of use for determining a4he

Country Status (12)

Country Link
US (3) US9822169B2 (enExample)
EP (1) EP2675911B1 (enExample)
JP (1) JP5887364B2 (enExample)
KR (3) KR102074141B1 (enExample)
CN (1) CN103492582B (enExample)
AU (1) AU2011359350B2 (enExample)
BR (1) BR112013021056B1 (enExample)
CA (1) CA2827618C (enExample)
ES (1) ES2834617T3 (enExample)
IL (1) IL227924B (enExample)
RU (1) RU2650778C2 (enExample)
WO (1) WO2012112160A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
CA2827618C (en) * 2011-02-17 2019-08-06 Fujirebio Diagnostics, Inc. Compositions and methods of use for the determination of he4a
CN106432492A (zh) * 2015-08-07 2017-02-22 广州瑞博奥生物技术有限公司 针对肿瘤标志物建立的抗体组合及其elisa方法
US11435354B2 (en) * 2016-02-19 2022-09-06 University Of Miyazaki Adenocarcinoma detection method
USD922352S1 (en) * 2019-01-04 2021-06-15 Dolby Laboratories Licensing Corporation Speaker
WO2020203478A1 (ja) * 2019-04-02 2020-10-08 コニカミノルタ株式会社 病態情報生成方法、病態情報生成システム、ｈｅ４糖鎖分析キット及びｈｅ４
CN111620939B (zh) * 2019-10-25 2021-01-01 南京市妇幼保健院 一种用于治疗或辅助治疗卵巢癌的多肽zyx36-58
USD940793S1 (en) * 2019-11-22 2022-01-11 Microsoft Corporation Electronic device
US20230243835A1 (en) * 2020-06-23 2023-08-03 Mitsui Chemicals, Inc. Adenocarcinoma detection method, and examination kit
WO2023195629A1 (ko) * 2022-04-08 2023-10-12 아주대학교산학협력단 He4 검출용 펩타이드 및 그 용도
CN117487018B (zh) * 2023-09-27 2024-05-17 武汉爱博泰克生物科技有限公司 抗人附睾分泌蛋白4的兔单克隆抗体及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US7270960B2 (en) 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
MXPA05011861A (es) * 2003-05-05 2006-02-17 Probiodrug Ag Uso de efectores de ciclasas de glutamato y glutaminil.
JP4744109B2 (ja) 2004-07-20 2011-08-10 トヨタ自動車株式会社 半導体装置とその製造方法
US7553944B2 (en) * 2004-07-21 2009-06-30 The University Of Hong Kong Human virus causing respiratory tract infection and uses thereof
ATE408828T1 (de) * 2005-02-16 2008-10-15 Dana Farber Cancer Inst Inc Verfahren zur erkennung eines ovarialkarzinoms
EP2982761B1 (en) 2006-01-04 2017-10-04 Fujirebio America, Inc. Use of he4 and other biochemical markers for assessment of endometrial and uterine cancers
AU2007211085A1 (en) 2006-01-27 2007-08-09 Tripath Imaging, Inc. Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor
KR20100015438A (ko) * 2007-03-09 2010-02-12 트리패스 이미징, 인코포레이티드 Ｈｅ4 모노클로날 항체 및 이의 사용 방법
EP2126577B1 (en) 2007-03-29 2013-03-13 Fujirebio Diagnostics, Inc. Use of he4 for assessment of breast cancers
CA2809368C (en) * 2010-08-26 2021-08-24 University Of Washington Through Its Center For Commercialization Methods for detecting anti-he4 antibodies and methods of diagnosis and/or prognosis of conditions associated with he4-expressing cells
CA2827618C (en) * 2011-02-17 2019-08-06 Fujirebio Diagnostics, Inc. Compositions and methods of use for the determination of he4a
US9980982B2 (en) * 2011-06-06 2018-05-29 Women & Infants Hospital Of Rhode Island HE4 based therapy for malignant disease

Also Published As

Publication number Publication date
IL227924A0 (en) 2013-09-30
ES2834617T3 (es) 2021-06-18
CA2827618C (en) 2019-08-06
JP2014507153A (ja) 2014-03-27
US20200325215A1 (en) 2020-10-15
CA2827618A1 (en) 2012-08-23
KR20200013118A (ko) 2020-02-05
KR20180014239A (ko) 2018-02-07
JP5887364B2 (ja) 2016-03-16
EP2675911A4 (en) 2015-04-01
AU2011359350B2 (en) 2016-07-14
EP2675911B1 (en) 2020-11-04
US9822169B2 (en) 2017-11-21
AU2011359350A2 (en) 2014-05-01
EP2675911A1 (en) 2013-12-25
KR101854110B1 (ko) 2018-05-04
US20150353629A1 (en) 2015-12-10
RU2013142334A (ru) 2015-03-27
KR102074141B1 (ko) 2020-02-07
BR112013021056B1 (pt) 2022-03-29
CN103492582B (zh) 2016-06-22
KR20140025348A (ko) 2014-03-04
US20180057575A1 (en) 2018-03-01
CN103492582A (zh) 2014-01-01
BR112013021056A2 (pt) 2016-08-09
AU2011359350A1 (en) 2013-09-12
RU2650778C2 (ru) 2018-04-17
WO2012112160A1 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
EP2675471A4 (en) HSA-RELATED COMPOSITIONS AND USE PROCESSES
PH12013501427A1 (en) Melanin modification compositions and methods of use
EP2678018A4 (en) COMBINATION OF CHINESE HEMMER AND USES THEREOF
IL232977B (en) Intra-episode dexmedetomidine preparations and methods of using them
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
AP3965A (en) Anthelminitic compounds and compositions and method of using thereof
EP2771030A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROTEINOPATHIES
PT2776567T (pt) Composições e métodos para o tratamento de citomegalovírus
EP2742154A4 (en) BIOMARKER COMPOSITIONS AND METHODS
EP2721179A4 (en) BIOMARKER COMPOSITIONS AND ASSOCIATED METHODS
EP2834322A4 (en) BIOCHARBON COMPOSITIONS AND METHODS OF USE
EP2603202A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF TAUOPATHIES
IL222227A0 (en) Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
HUE043894T2 (hu) Koagulációt elõsegítõ vegyületek és alkalmazásuk módszerei
HUE046750T2 (hu) Az ibuprofen transzdermális készítményei és azok felhasználási módjai
GB201411462D0 (en) Prebiotic formulations and methods of use
SG11201400668SA (en) Wnt compositions and therapeutic uses of such compositions
IL227924A0 (en) Preparations and methods of use for determining a4he
IL225389A0 (en) Antibody preparations and methods of use
EP2731601A4 (en) EOSINOPHILIC PEROXIDASE COMPOSITIONS AND METHOD FOR THEIR USE
EP2709999A4 (en) QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE
EP2668044A4 (en) COMPOSITIONS AND THEIR USE
ZA201308892B (en) Compositions and methods
ZA201407978B (en) Compositions and methods for the alteration of xlhed phenotypes
IL239623A0 (en) Methods and preparations for administering oxybutynin

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed